| For: | Shetty S, Suvarna R, Ambrose Fistus V, Modi S, Pappachan JM. Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis. World J Hepatol 2025; 17(5): 105706 [PMID: 40501478 DOI: 10.4254/wjh.v17.i5.105706] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i5/105706.htm |
| Number | Citing Articles |
| 1 |
Matheus Henrique Gonçalves de Souza, Pedro Miguel Mattos Nogueira, Cristiane Alves Villela-Nogueira. Metabolic dysfunction-associated steatotic liver disease and diabetes: Together against the heart. World Journal of Hepatology 2025; 17(9): 109737 doi: 10.4254/wjh.v17.i9.109737
|
| 2 |
Abul Bashar Mohammad Kamrul-Hasan, Sanja Borozan, Sweekruti Jena, Lakshmi Nagendra, Deep Dutta, Saptarshi Bhattacharya, Md Saiful Islam, Joseph M Pappachan. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. World Journal of Gastrointestinal Pharmacology and Therapeutics 2025; 16(3): 110709 doi: 10.4292/wjgpt.v16.i3.110709
Abstract(61) |
Core Tip(60) |
Full Article(HTML)(488)
|
Full Article with Cover (PDF)-819K(35)
|
Audio-625K(7)
|
Peer-Review Report-261K(23)
|
Answering Reviewers-204K(20)
|
Supplementary Material-571K(26)
|
Full Article (PDF)-567K(68)
|
Full Article (XML)-161K(20)
|
Times Cited (0)
|
Total Visits (2861)
|
Open
|
| 3 |
Amedeo Lonardo, Ralf Weiskirchen. PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100590
|
